VXRT Q3 2025 Earnings Call Summary | Stock Taper
Logo
Pricing Log In
VXRT

VXRT — Vaxart, Inc.

NASDAQ

Q3 2025 Earnings Call Summary

November 13, 2025

VXRT Q3 2025 Earnings Call Summary

  1. Key Financial Results and Metrics:

    • Revenue for Q3 2025 was $72.4 million, a significant increase from $4.9 million in Q3 2024, primarily driven by a BARDA contract awarded in June 2024.
    • Cash, cash equivalents, and investments totaled $28.8 million at the end of Q3 2025.
    • Following a partnership with Dynavax, Vaxart's cash runway is now projected to extend into Q2 2027.

  2. Strategic Updates and Business Highlights:

    • Vaxart announced a partnership with Dynavax, which includes a $25 million upfront license fee and a $5 million equity investment. The deal could yield up to $700 million in total fees and royalties for Vaxart's oral COVID-19 vaccine candidate.
    • The agreement allows Vaxart to retain operational control through the ongoing Phase IIb clinical trial, with Dynavax potentially taking over post-trial development.
    • Positive Phase I results for Vaxart's second-generation norovirus vaccine were reported, showing significantly improved antibody responses compared to first-generation constructs.

  3. Forward Guidance and Outlook:

    • Vaxart is on track to report 12-month top-line data from the sentinel cohort of the COVID-19 trial in Q1 2026 and from the larger cohort in Q4 2026.
    • The company anticipates initiating the next clinical trial for the norovirus program in 2026, contingent on securing funding.

  4. Bad News, Challenges, or Points of Concern:

    • Vaxart received a stop work order from BARDA on its Phase IIb clinical study, halting enrollment but allowing follow-up work for already enrolled subjects.
    • The company faces challenges in securing partnerships for its norovirus program, with future clinical trials dependent on external funding and partnership agreements.

  5. Notable Q&A Insights:

    • Dynavax's decision to partner now rather than wait for additional data was attributed to the strong fit between the companies and the potential of Vaxart's oral vaccine platform.
    • Vaxart's management emphasized the ongoing interest from potential partners for its pipeline assets, including norovirus, HPV, and flu vaccines, following the validation from the Dynavax partnership.
    • Questions regarding the COVID-19 market potential highlighted a perceived decline in vaccination rates, but management remains optimistic about the advantages of their oral delivery method and its potential to address ongoing COVID-19 challenges.